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A B S T R A C T
Aim: To ascertain present United Kingdom (UK) management processes for epilepsy in older people.
Method: This was a general practice notes review of people being treated for epilepsy 60 years and over.
Results: The cohort of 110was from six practices. Seizure frequency in older people with epilepsy appears
lower than in general; 75% are seizure free. This compareswith 40–60% of people in other general practice
note reviews and audits, where age is not a factor. Out of the people still having seizures over half have
less than one seizure per month.
Monotherapy rates are similar to the population in general. Nobody was taking more than two AEDs.
There is evidence of new AED use, especially lamotrigine; it is the most commonly prescribed AED in
those diagnosed in later life.
Geriatricians appear to receive virtually no referrals for the diagnosis of epilepsy. General physicians,
psychiatrists and neurologists receive many more. Geriatricians and general physicians appear never to
follow up older people with epilepsy; GPs following up 91%, and neurologists and specialist nurses 9%.
Conclusions: Seizure frequency in older people with epilepsy is generally low. Geriatricians appear to
receive virtually no referrals for the diagnosis or management of epilepsy in older people. Follow up is
mainly undertaken by GPs. Although lamotrigine has a difﬁcult dosing schedule, which may be confusing
for some older people, its use is high perhaps reﬂecting recent guidelines and evidence.
These results may be peculiar to the geographical area used, so other work is needed to conﬁrm or
refute these ﬁndings.
 2008 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Epilepsy is the third most common neurological disorder in old
age after dementia and stroke.1 The elderly population is increasing
rapidly,more than 20% of theworld populationwill be over 60 years
of age by 2050,2 therefore the prevalence of epilepsy in old age will
increase and should be regarded as a signiﬁcant public health issue
as well as an important clinical problem.
There is a rise in the incidence of epilepsy in the early years of
life and a second more marked rise in those 60 years of age and
above; older people are now the group with the highest incidence
of epilepsy in the general population.3,4,5 It is now a common
occurrence for the older patient to present with epilepsy in general
practice.6 The Rochester Minnesota survey found that both single* Corresponding author at: Department of Neurosciences, York Hospital,
Wigginton Road, York YO31 8HE, United Kingdom. Tel.: +44 1484 647895.
E-mail address: b.chappell@neuroeducation.org.uk (B. Chappell).
1059-1311/$ – see front matter  2008 British Epilepsy Association. Published by Else
doi:10.1016/j.seizure.2008.06.003unprovoked seizures and epilepsy increased sharplywith age.7 The
active prevalence rate of epilepsy among persons over 65 is
approximately 1.5%, about twice the rate in younger adults.8
Despite this considerable public health need, there are fewer
academic publications concerning epilepsy and its treatment in
older people than other age groups and much less is known about
many aspects of care. In this United Kingdom (UK) general practice
notes review we present data on an unselected community based
cohort that primarily looks at; seizure frequency, drug treatment,
diagnostic referral patterns and continuing care referral patterns.
The papermentions andpresents data on, amongothers, services
provided byboth general practitioners andgeneral physicians in the
UK. For clariﬁcation, within the UK National Health Service general
physicianswork inhospital (secondarycare)with thosebetween the
ages of 16–75 and general practitioners in community care (primary
care) throughout the whole age range. Even though referred to as
‘‘generalists’’ the physicians in secondary carewould be regarded as
having more specialised knowledge and general practitioners refer
on to the physicians where it is thought applicable.vier Ltd. All rights reserved.
Table 3
Who made the diagnosis
Number Percent Valid percent Cumulative percent
GP 5 4.5 9.6 9.6
General physician 28 25.5 53.8 63.5
Geriatrician 1 0.9 1.9 65.4
Neurologist 13 11.8 25.0 90.4
Psychiatrist 3 2.7 5.8 96.2
Neurosurgeon 2 1.8 3.8 100.0
Total 52 47.3 100.0
Missing data 58 52.7
Total 110 100.0
Table 4
Seizure frequency per annum
Seizures per annum Number Percent Valid percent Cumulative percent
Seizure free 70 63.6 75.3 75.3
1 5 4.5 5.4 80.6
3 2 1.8 2.2 82.8
4 1 0.9 1.1 83.9
5 2 1.8 2.2 86.0
6 2 1.8 2.2 88.2
9 1 0.9 1.1 89.2
12 8 7.3 8.6 97.8
36 1 0.9 1.1 98.9
728 1 0.9 1.1 100.0
Total 93 84.5 100.0
Missing data 17 15.5
Total 110 100.0
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An audit data sheet was initially designed by adapting the
protocol used by Chappell and Hall in their previous review of
general practice epilepsy care that had no age limits.9 After visits to
two general practices that involved looking at data on computer
and in patient notes this was then updated to reﬂect the basic data
on epilepsy in older people thatwas likely to be available in a group
of practices.
Ten general practices were approached and asked if they were
willing to take part in the review.
The letter of invitation explained: the main aim of the review,
namely to consider the present care for people 60 years of age and
over with epilepsy; that an adapted previously designed data
collection sheet would be followed and that practices could either
collect their own data or one of the research team would support
them in the collection of their data.
Six practices opted to take part and all decided that they would
welcome support in collecting the data.
Data was collected over a period of three months, entered into
SPSS for Windows 14.0 and analysed.
Results
Background information for full cohort (N = 110)
Age (N = 110) (Table 1)
Sex (N = 110)
Fifty six (51%) were male and 54 (49%) were female.
Age at diagnosis (N = 90) (Table 2)
Who made the diagnosis (N = 52)
For people diagnosed in childhood (therefore by deﬁnition
diagnosed many years ago) the correspondence pertaining to this
in patient notes was either impossible to ﬁnd or non-speciﬁc about
who did what, hence the absence of paediatricians in the data
(Table 3).Table 1
Age
Age groupings Number Percent Valid percent Cumulative percent
60–69 44 40.0 40.0 40.0
70–79 45 40.9 40.9 80.9
80–89 20 18.2 18.2 99.1
90+ 1 0.9 0.9 100.0
Total 110 100.0 100.0
Table 2
Age at diagnosis
Age groupings Number Percent Valid percent Cumulative percent
0–16 9 8.2 10.0 10.0
17–59 44 40.0 48.9 58.9
60+ 37 33.6 41.1 100.0
Total 90 81.8 100.0
Missing data 20 18.2
Total 110 100.0Seizure frequency per annum (N = 93) (Table 4)
Number of AEDs being taken (N = 110)
Fourteen people (13%) were taking no AEDs, 76 (69%) were
taking one and 20 (18%) were taking two.
Name of AEDs being taken (N = 110)
When combining monotherapy and polytherapy the most
commonly used AEDs were phenytoin (N = 37), sodium valproate
(N = 29) and lamotrigine (N = 15) (Table 5).Table 5
Name of AEDs
Number Percent Valid percent Cumulative
percent
None 14 12.7 12.7 12.7
Carbamazepine 11 10.0 10.0 22.7
Clonazepam 1 0.9 0.9 23.6
Gabapentin 1 0.9 0.9 24.5
Lamotrigine 11 10.0 10.0 34.5
Levetiracetam 1 0.9 0.9 35.5
Phenobarbitone 7 6.4 6.4 41.8
Phenytoin 21 19.1 19.1 60.9
Primidone 1 0.9 0.9 61.8
Sodium Valproate 21 19.1 19.1 80.9
Topiramate 1 0.9 0.9 81.8
Phenytoin Phenobarbitone 8 7.3 7.3 89.1
Phenytoin Lamotrigine 3 2.7 2.7 91.8
Phenytoin Gabapentin 1 0.9 0.9 92.7
Phenytoin Sodium Valproate 4 3.6 3.6 96.4
Sodium Valproate Lamotrigine 1 0.9 0.9 97.3
Sodium Valproate Carbamazepine 1 0.9 0.9 98.2
Topiramate Sodium Valproate 2 1.8 1.8 100.0
Total 110 100.0 100.0
Table 6
Date of last visit to surgery in months—epilepsy
Number of months Number Percent Valid percent Cumulative percent
1 14 12.7 15.9 15.9
2 7 6.4 8.0 23.9
3 20 18.2 22.7 46.6
4 6 5.5 6.8 53.4
5 4 3.6 4.5 58.0
6 4 3.6 4.5 62.5
7 2 1.8 2.3 64.8
9 1 0.9 1.1 65.9
10 5 4.5 5.7 71.6
11 4 3.6 4.5 76.1
12 2 1.8 2.3 78.4
13 5 4.5 5.7 84.1
15 2 1.8 2.3 86.4
16 1 0.9 1.1 87.5
19 1 0.9 1.1 88.6
23 2 1.8 2.3 90.9
24 2 1.8 2.3 93.2
28 1 0.9 1.1 94.3
29 1 0.9 1.1 95.5
33 1 0.9 1.1 96.6
34 2 1.8 2.3 98.9
138 1 0.9 1.1 100.0
Total 88 80.0 100.0
Missing data 22 20.0
Total 110 100.0
Table 8
Names of the AEDs
Number Percent Valid
percent
Cumulative
percent
None 3 8.1 8.1 8.1
Carbamazepine 4 10.8 10.8 18.9
Lamotrigine 9 24.3 24.3 43.2
Levetiracetam 1 2.7 2.7 45.9
Phenytoin 4 10.8 10.8 56.8
Sodium Valproate 8 21.6 21.6 78.4
Topiramate 1 2.7 2.7 81.1
Phenytoin Phenobarbitone 1 2.7 2.7 83.8
Phenytoin Lamotrigine 2 5.4 5.4 89.2
Phenytoin Gabapentin 1 2.7 2.7 91.9
Phenytoin Sodium Valproate 2 5.4 5.4 97.3
Sodium Valproate Lamotrigine 1 2.7 2.7 100.0
Total 37 100.0 100.0
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Ninety four (91%) were being followed up by their GP, 4 (4%) by
a neurologist and 5 (5%) by a specialist epilepsy nurse.
Date of the person’s last visit to the general practice surgery for their
epilepsy (N = 88) (Table 6)
Those diagnosed at 60 years of age or above (N = 37)
The age range of this sub-cohort was 64-91 years. There were
more males (22 [60%]) than females (15 [40%]).
Who made the diagnosis (N = 27)
Table 7 shows who made the diagnosis.
Seizure frequency per annum (N = 34)
Twenty seven (79%) were seizure free and only two (6%) had
more than one seizure per month. There was no record of seizure
frequency in the notes for three people.
Number of AEDs being taken (N = 37)
Three people (8%) were taking no AEDs, 27 (73%) were taking
one and 7 (19%) were taking two.Table 7
Who made the diagnosis
Number Percent Valid percent Cumulative percent
General Physician 16 43.2 59.3 59.3
Geriatrician 1 2.7 3.7 63.0
Neurologist 8 21.6 29.6 92.6
Psychiatrist 2 5.4 7.4 100.0
Total 27 73.0 100.0
Missing data 10 27.0
Total 37 100.0Names of the AEDs being taken (N = 37)
When combining monotherapy and polytherapy the most
commonly used AEDs were lamotrigine (N = 11), sodium valproate
(N = 10) and phenytoin (N = 9) (Table 8).
Who follows people up (N = 35)
Twenty nine (84%)were being followed up by their GP, 3 (8%) by
a neurologist and 3 (8%) by a specialist epilepsy nurse.
Discussion
This cohort of people 60 years and over with epilepsy was both
typical and untypical when compared with epilepsy cohorts of all
age groups recruited from UK general practice note reviews and
audits. The split between the sexes and the use of monotherapy
was virtually identical.9,10 Whereas seizure frequency was much
lower suggesting that seizures are easier to treat in older
people.9,10 Three quarters were seizure free (79% in those
diagnosed 60 and over) and of those still having seizures over
half had less than one seizure per month. This is interesting, as it is
fair to assume that for those in the cohort whose epilepsy
developed in later life that it would be either symptomatic or
cryptogenic and therefore normally associated with being difﬁcult
to treat.
AED use was quite unusual; notably the very low number of
people taking carbamazepine. As carbamazepine is an enzyme
inducing AED11 you can argue that it is more difﬁcult to use in
those highly likely to be taking other non-epilepsy medications.
There was evidence of the use of newer AEDs launched since 1989,
especially lamotrigine. In fact, lamotrigine was the most com-
monly used AED in those diagnosed at age 60 or over. We can
provide no direct insight from the physicians involved into why
this might be, but it is very different from what you would ﬁnd in
those diagnosed before 60 years of age.10,12 Lamotrigine is not the
easiest AED to introduce and it could be argued that it might be
quite a challenge for some older people to follow the complex
initial dosage regime. The recent SANAD study (covering partial
[focal] seizures), plus earlier data and guidelines support the use of
lamotrigine in older people,13–16 but despite this it is overall usage
did seem a little high.
Fourteen people were not taking AEDs. Some practices had
epilepsy databases, but some did not and it is possible that there
were more people with epilepsy not being treated as some
practices identiﬁed their patients by searching prescriptions (both
computer generated and handwritten). We obtained limited data
for this group. All were being followed up by their GP. Their age
range was 62–84 years. We only had seizure frequency data for
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having up to one seizure per month. It is interesting that two
people did not opt for treatment.We do not know speciﬁcally why,
but there are logical reasons for this in older people, i.e. they may
not be able to drive for other reasons or want to work, etc.,
therefore seizure freedom, unlike many younger people, might not
be their ultimate goal?
Twenty one people (19%) were taking phenytoin montherapy.
In modern practice this may seem high. It wasmainly explained by
17 (90%) peoplewhowere diagnosed quite a long time ago. Also, 17
of the 21 (90%) were seizure free, a higher ﬁgure than the cohort’s
seizure freedom in general; so a policy of ‘‘leave well alone’’ has
probably been judicious.
Perhaps the most remarkable part of the note review was the
organization of care. Interestingly the National Institute for Clincal
Excellence (NICE) guidelines17 do not include a speciﬁc advisory
section for older people, even though epilepsy is common in this
age group.18 Arguably the most important statement in the
guideline was as follows:
‘‘The Guideline Development Group (GDG) felt strongly that
older people with epilepsy should have access to the same range of
investigations and treatment as any other group with epilepsy.’’17
The data in this study would suggest that care for older people
differs dramatically from other age groups, therefore not fulﬁlling
the NICE advice.17 This is at its most notable when compared with
children. Previous work suggests that the vast majority of children
are diagnosed and regularly followed up by specialist staff
(paediatricians),19 whereas in this older age group only one person
was diagnosed andnobody at allwas being followedupby specialist
staff particular to the age group (geriatricians), although 9% did
continue to see a neurologist or specialist nurse, both these latter
professionals groups, of course, being very applicable for this group
of people’s care. As 25% of people continued to have seizures and 9%
were being seen by ‘‘specialist care’’ this means approximately two
thirds of people still having seizures were being solely managed by
their GP. All the people who were initially seen by a general
physician are not being followed up by the same service at all.
Why should GPs be deemed skilled to follow up people 60 and
over, when they are obviously not deemed the same for children
and adolescents? Is epilepsy easier to manage in older people?
Tallis certainly thinks not.20 In his paper he outlines the particular
difﬁculties of diagnosis, choice of AED and advice about lifestyle.
We agree with this. Yes, there is the argument that seizure
frequency would appear to be lower, therefore management
simpler, but this is not looking at the full picture and impact.
Surely, the complexities of epilepsy itself and living with epilepsy
in this age group dictate that more than 9% of people will need
specialist follow up?
The newGeneralMedical Services (GMS) contract outlined some
standards for managing people with epilepsy in general practice.21
The standards were not ambitious. One standard stated that all
people with epilepsy should be reviewed within any 15 month
period.Eighty-sixpercentof thiscohortmetthis standard.Wedonot
have any detail of what actually happened at these reviews, but it is
encouraging that such a large percent had been seen.
Conclusion
Seizure frequency in older people with epilepsy is generally
low; 75% being seizure free. Of those still having seizures over half
have less than one seizure per month.In our study geriatricians appear to receive virtually no referrals
for the diagnosis of epilepsy, despite there being a specialist
epilepsy clinic for older people available within a reasonable
travelling distance. Psychiatrists, neurologists (very applicable)
and most notably general physicians receive the vast majority of
referrals. Also, geriatricians appear not to follow up older people
with epilepsy; the vast majority of this work is completed by GPs,
which varies dramatically from children with epilepsy.
AED use is different, especially for lamotrigine and carbama-
zepine.
It should be noted that the organization of care results maybe
peculiar to the geographical area used, so other work is needed to
conﬁrm or refute these ﬁndings.
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